Enhanced Overall Survival and Tumor Reduction in EUS-RFA for Unresectable Pancreatic Adenocarcinoma

Researchers assessed EUS-RFA in 26 patients with unresectable pancreatic ductal adenocarcinoma, showing technical success in all cases and no major adverse events. Six months post-EUS-RFA, 42.3% of patients had improved overall survival and significant performance status enhancement. Tumor reduction and post-treatment necrotic areas were observed, while metastatic disease negatively impacted survival. EUS-RFA proved safe and potentially beneficial in locally advanced and non-metastatic cases, suggesting its role as targeted therapy for unresectable pancreatic adenocarcinoma.